Table 2 Plasma pharmacokinetic parameters of intact oxaliplatin and free platinum in colorectal cancer patients (n=19)
AUC0-t | Cmax | Cl | Vss | MRT | |||
|---|---|---|---|---|---|---|---|
(μmol/L*h) | (μmol/L) | (L/h) | (L) | (h) | |||
Oxaliplatin dose | Study treatment | ||||||
All (n = 19) | Intact oxaliplatin | Placebo | 15.6 (3.80) | 7.62 (1.92) | 33.6 (7.70) | 57.2 (15.5) | 1.68 (0.10) |
Ca/Mg | 14.8 (3.69) | 7.31 (1.91) | 35.3 (9.76) | 59.3 (14.9) | 1.70 (0.13) | ||
Ratio* | 0.95 (0.90-1.01) | 0.96 (0.90-1.02) | 1.05 (0.99-1.12) | 1.06 (0.99-1.13) | 1.01 (0.99-1.04) | ||
Free platinum | Placebo | 20.2 (4.12) | 9.24 (1.52) | 25.9 (6.65) | 48.4 (11.3) | 1.87 (0.10) | |
Ca/Mg | 19.8 (4.18) | 9.52 (1.55) | 26.8 (6.03) | 50.9 (9.95) | 1.90 (0.16) | ||
Ratio* | 0.98 (0.93-1.03) | 1.03 (0.95-1.12) | 1.04 (0.97-1.10) | 1.05 (0.99-1.12) | 1.02 (0.99-1.05) | ||
130 mg/m2 (n = 15) | Intact oxaliplatin | Placebo | 16.9 (3.32) | 8.28 (1.69) | 34.5 (7.98) | 57.3 (14.3) | 1.66 (0.07) |
Ca/Mg | 15.8 (3.51) | 8.01 (1.63) | 36.7 (10.2) | 60.7 (17.8) | 1.66 (0.07) | ||
Ratio* | 0.93 (0.86-1.02) | 0.97 (0.90-1.04) | 1.06 (0.98-1.15) | 1.06 (0.98-1.14) | 1.00 (0.98-1.02) | ||
Free platinum | Placebo | 21.8 (3.09) | 9.83 (1.06) | 26.8 (6.57) | 49.7 (11.7) | 1.85 (0.05) | |
Ca/Mg | 21.3 (4.45) | 10.0 (1.31) | 27.8 (6.01) | 52.2 (9.82) | 1.88 (0.16) | ||
Ratio* | 0.98 (0.92-1.04) | 1.02 (0.94-1.10) | 1.04 (0.97-1.12) | 1.05 (0.97-1.14) | 1.01 (0.98-1.05) | ||
85 mg/m2 (n = 4) | Intact oxaliplatin | Placebo | 11.4 (1.10) | 5.58 (0.74) | 30.7 (6.34) | 53.8 (12.5) | 1.75 (0.18) |
Ca/Mg | 11.4 (1.03) | 5.19 (0.53) | 30.7 (5.81) | 57.5 (10.3) | 1.88 (0.16) | ||
Ratio* | 1.00 (0.82-1.22) | 0.93 (0.74-1.17) | 1.00 (0.87-1.15) | 1.07 (0.88-1.31) | 1.07 (0.97-1.18) | ||
Free platinum | Placebo | 15.3 (4.12) | 7.32 (1.52) | 22.9 (6.89) | 43.9 (9.17) | 1.92 (0.21) | |
Ca/Mg | 15.0 (2.79) | 7.91 (1.35) | 23.3 (5.17) | 46.4 (10.4) | 1.99 (0.17) | ||
Ratio* | 0.98 (0.83-1.16) | 1.08 (0.73-1.60) | 1.02 (0.86-1.21) | 1.06 (0.97-1.15) | 1.03 (0.91-1.17) |